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Abstract
Purpose—Epigenetic dysregulation is known to be an important contributor to myeloma 
pathogenesis but, unlike in other B cell malignancies, the full spectrum of somatic mutations in 
epigenetic modifiers has not been previously reported. We sought to address this using results 
from whole-exome sequencing in the context of a large prospective clinical trial of newly 
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diagnosed patients and targeted sequencing in a cohort of previously treated patients for 
comparison.
Experimental Design—Whole-exome sequencing analysis of 463 presenting myeloma cases 
entered in the UK NCRI Myeloma XI study and targeted sequencing analysis of 156 previously 
treated cases from the University of Arkansas for Medical Sciences. We correlated the presence of 
mutations with clinical outcome from diagnosis and compared the mutations found at diagnosis 
with later stages of disease.
Results—In diagnostic myeloma patient samples we identify significant mutations in genes 
encoding the histone 1 linker protein, previously identified in other B-cell malignancies. Our data 
suggest an adverse prognostic impact from the presence of lesions in genes encoding DNA 
methylation modifiers and the histone demethylase KDM6A/UTX. The frequency of mutations in 
epigenetic modifiers appears to increase following treatment most notably in genes encoding 
histone methyltransferases and DNA methylation modifiers.
Conclusions—Numerous mutations identified raise the possibility of targeted treatment 
strategies for patients either at diagnosis or relapse supporting the use of sequencing-based 
diagnostics in myeloma to help guide therapy as more epigenetic targeted agents become 
available.
Keywords
myeloma; whole-exome sequencing; epigenetic modifiers
Introduction
Myeloma is a malignancy of plasma cells, terminally differentiated B cells involved in the 
immune response. Despite advances in therapy over the last 10 years subgroups of patients 
diagnosed with myeloma continue to have poor outcomes and most inevitably relapse. A 
better understanding of the genetic and epigenetic abnormalities that contribute to disease 
pathogenesis is required in order to develop new targeted treatment strategies.
The myeloma clone is thought to be immortalised following the acquisition of a 
translocation into the immunoglobulin heavy chain locus (t(4;14), t(6;14), t(11;14), t(14;16) 
and t(14;20)) or hyperdiploidy. The clone then evolves via the subsequent gain of further 
genetic or epigenetic events.(1) Epigenetic dysregulation is known to be an important 
contributor to myeloma progression, but the full extent of its role in the pathogenesis of 
disease and high risk behaviour is uncertain.(2) A key example of the relevance and role of 
epigenetic deregulation in myeloma comes from our understanding of the subgroup of 
patients with the t(4;14), which results in the juxtaposition of MMSET, a H3K36 
methyltransferase, to the immunoglobulin heavy chain locus enhancer. The resulting 
overexpression of MMSET leads to a histone methylation pattern, characterised by increased 
H3K36me2 and decreased H3K27me3, along with a distinct and aberrant DNA methylation 
pattern.(3) Downstream events occurring as a result of this primary event include changes in 
expression of genes involved in the cell cycle, apoptosis and cell adhesion.(4–7) Patients 
carrying the t(4;14), around 15% of myeloma cases at clinical diagnosis (8, 9), tend to 
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respond to treatment but relapse early and have a shorter overall survival, though since the 
use of proteasome inhibition there is evidence that this poor prognosis is ameliorated.
The impact of mutation on epigenetic modifiers in myeloma has also been reported, with 
inactivation of the histone demethylase, KDM6A/UTX, seen in 10% of samples (10), and 
mutations affecting the histone methyltransferase, MLL (11) the best documented. The 
recognition of mutations in MLL followed the first sequencing study of myeloma patients 
where expression of the homeobox protein, HOX9A, was suggested to be regulated by MLL.
(11) More recently an activating mutation of MMSET at E1099K was found in the MM.1S 
myeloma cell line with the same downstream effect as MMSET overexpression due to the 
t(4;14). (12)
Based on these considerations we sought to investigate the role of mutations in epigenetic 
modifiers in myeloma and how such mutations might contribute to disease pathogenesis. We 
used whole exome sequencing to examine the spectrum of mutations in epigenetic modifiers 
in a series of 463 newly diagnosed patients uniformly treated as part of the UK NCRI 
Myeloma XI clinical trial (MyXI) and describe the clinical implication of mutations in terms 
of their effect on progression-free and overall survival. Previously reported results from this 
dataset identified 15 significantly mutated genes in myeloma, a distinct APOBEC signature 
associated with maf translocations and the link between these factors and prognosis.(13, 14) 
Here we extend these analyses with a focus on highlighting epigenetic mutations important 
in the pathogenesis of myeloma and compare the frequency of mutations at diagnosis to later 
stages of disease, using a dataset from the University of Arkansas for Medical Sciences 
(UAMS). This analysis comprises the largest series of newly diagnosed myeloma patients 
sequenced to date and provides important insights into the role of epigenetics in the disease, 
as well as highlighting potential avenues for future research and targeted treatment 
development.
Materials and Methods
Whole exome sequencing at diagnosis – Myeloma XI
Methods used for the analysis of patient material have been previously published (13, 14) 
but are summarised below:
Samples were taken, following informed consent and prior to treatment commencement, 
from 463 patients newly diagnosed with symptomatic myeloma and enrolled in the UK 
NCRI Myeloma XI trial (NCT01554852). The study was approved by the NHS Health 
Research Authority, National Research Ethics Service Committee and by local review 
committees at all participating centres. The study randomised patients between triplet 
immunomodulatory drug (IMiD) inductions with thalidomide vs lenalidomide, prior to 
subsequent randomisations comparing consolidation and maintenance approaches. The 
demographics of the patients included in this analysis have been published and are 
reproduced in Supplementary Table 1. (14) Progression-free (PFS) and overall survival (OS), 
measured from initial randomisation, had median follow up of 25 months, 95% CI 
[24.3,26.2]. The median PFS was 26.6 months, 95%CI [23.6,29.9] and the median OS was 
not reached but the 3 year OS was 66%, 95%CI [60,73].
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CD138+ plasma cells were isolated from bone marrow cells using MACSorting (Miltenyi 
Biotech, Bisley, UK), lysed in RLT+ buffer and DNA/RNA extracted using the AllPrep kit 
(Qiagen, Manchester, UK). White blood cells were isolated from peripheral blood, purified 
by Ficoll-Pacque and DNA extracted using the QIAamp DNA mini kit (Qiagen).
DNA from both tumour and peripheral blood samples was used in the exome capture 
protocol.(13, 15) RNA baits were designed against the human exome with additional custom 
baits tiling the IGH, IGK, IGL and MYC loci to detect the major translocations. Four exome 
samples were pooled and run on one lane of a HiSeq 2000 (Illumina, Hinxton, UK) using 
76-bp paired end reads. Data quality and metrics processing, processes for somatic mutation 
calling and molecular and copy number assessments are described fully elsewhere (13).
Copy Number Estimation and Cancer Clonal Fraction – Myeloma XI
Copy number across the exome was determined using Control-FREEC (16) utilizing 500bp 
bins, each overlapping with the subsequent and previous 250bp. A minimum average read 
depth of 50 was required in the control samples, with at least two neighbouring bins required 
to show CN aberration to call a region as gained or lost. Copy number profiles for a series of 
26 chromosomal regions were compared with copy number values previously estimated by 
multiplex-ligated probe amplification tests.(17) To ensure a reliable estimation of copy 
number, only cases with an F correlation above 50% were used for subsequent analyses 
(370/463).
Cancer clonal fraction was calculated, (18) as the proportion of tumour cells containing an 
SNV using the equation:
Where CCF=cancer clonal fraction (proportion of cells containing the mutation), CN=copy 
number at that site, r=number of reads containing the mutation at that site, R=total number 
of reads at that site.
Further data analysis – Myeloma XI
Lists of epigenetic modifiers were curated using database searches and previous publications 
(Supplementary Table 2) with genes divided into eight classes: Core/linker histones (n=79), 
histone demethylases (n=21), histone methyltransferases (n=40), histone deacetylases 
(n=20), histone acetyltransferases (n=25), DNA modifiers (n=8), readers (n=17) and 
chromatin assembly/remodelling (n=46). These lists were used to interrogate the results of 
the sequencing analysis in order to calculate the percentage of patients with a mutation in 
each gene and in each class.
For all genes mutated in more than 1% of patients, mutations were mapped to the relevant 
regions of the protein using Protein Paint (19) and the Catalogue of Somatic Mutations in 
Cancer (COSMIC) database was searched to look for previously identified variants at the 
same amino acid residue in other tumours.(20) Multiple sequence alignment of histone 1 
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genes was performed by inputting sequences from FASTA files obtained from uniprot.org 
into ClustalW2. Mutations were annotated in GeneDoc. The likely effect of mutations was 
assessed using SIFT analysis. (21)
Deletions in KDM6A were identified using an algorithm to detect deletion of whole exons 
(windows defined as the regions used in the Agilent exome capture). This was done by 
comparing the read depth between the tumour and normal samples. The mean depth across 
the window was required to be > 0.2 of the median depth in the normal sample and < 0.06 in 
the tumour sample, with the normal value being at least 8× greater than the tumour value. 
Positive findings using this method were confirmed or excluded following visualisation in 
Integrated Genome Viewer (IGV).
Survival curves were plotted (Kaplan-Meier) and the statistical significance of the difference 
between curves tested using the Logrank test, with P<0.05 taken as the level of significance. 
Multivariate analysis was performed using the cox-regression model inputting the epigenetic 
mutations with a significant impact on survival by univariate Logrank statistic and other 
standard clinical factors known to influence survival in myeloma patients.
Targeted sequencing in previously treated patients – UAMS
156 patients who had previously undergone treatment had bone marrow samples taken and 
genomic profiling (FoundationOne Heme®; Foundation Medicine) performed as part of their 
disease reassessment work-up. Review of this data was approved by the UAMS institutional 
review board. The demographics of the patients included in this analysis are shown 
Supplementary Table 3. CD138+ cells were isolated from bone marrow aspirates as 
previously (22) with DNA and RNA extracted using the Puregene and RNeasy kits (Qiagen) 
respectively. Samples were submitted to a CLIA-certified, New York State and CAP-
accredited laboratory (Foundation Medicine, Cambridge MA) for NGS-based genomic 
profiling. Hybridization capture was applied to ≥ 50ng of extracted DNA or RNA for 405 
cancer related genes and select intronic regions from 31 genes (FoundationOne Heme DNA 
only, n=405); targeted RNA-seq for rearrangement analysis was performed for 265 genes 
frequently rearranged in cancer. Sequencing of captured libraries was performed (Illumina 
HiSeq 2500) to a median exon coverage depth of >250×, and resultant sequences were 
analyzed for base substitutions, insertions, deletions, copy number alterations (focal 
amplifications and homozygous deletions) and select gene fusions, as previously described.
(23, 24) To maximize mutation-detection accuracy (sensitivity and specificity) in impure 
clinical specimens, the test was previously optimized and validated to detect base 
substitutions at a ≥5% mutant allele frequency (MAF) and indels with a ≥10% MAF with 
≥99% accuracy.(23, 24) The mutations reported on the F1 test were all manually, 
individually reviewed. Mutations were retained and included in the subsequent analysis only 
if either they were classified by Foundation Medicine as definitely ‘known’, were frameshift, 
nonsense or splice-site mutations or if a mutation affecting the same amino acid residue had 
been previously recognised in another tumour (determined by analysis of Catalogue of 
Somatic Mutations in Cancer (COSMIC) datasets directly (20) and via visualisation using 
the St Jude’s PeCan data portal. (25))
Pawlyn et al. Page 5
Clin Cancer Res. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Due to the greater depth of the FoundationOne Heme® test a cut off for mutations being 
present in ≥5% reads was applied to this dataset (mutations that could have been detected 
using the depth achieved in the MyXI study). Epigenetic genes from the list in 
Supplementary Table 2 (and analysed in the MyXI data) which were also sequenced in the 
UAMS dataset are shown in Supplementary Table 4. This comprises: Core/linker histones 
(n=12), histone demethylases (n=5), histone methyltransferases (n=11), histone deacetylases 
(n=3), histone acetyltransferases (n=4), DNA modifiers (n=4), readers (n=2) and chromatin 
assembly/remodelling (n=9).
The percentage of patients with mutations in each class of epigenetic modifier were 
compared between the MyXI dataset and the UAMS dataset using the z-test, multiple testing 
was corrected for using the Bonferroni method. Since CCF could not be calculated for the 
patients in the UAMS dataset (due to the absence of copy number data) the variant allele 
frequencies were compared for those genes with at least 2 mutated samples in both datasets.
Results
Whole exome sequencing was performed on samples from 463 patients in the Myeloma XI 
trial prior to treatment. We identified mutations in genes encoding epigenetic modifiers in 
over half (53%) of patients. 20 epigenetic modifier genes were mutated in at least 5/463 
(>1%) of individuals with frequencies shown in Table 1, cancer clonal fraction (CCF), 
shown in Figure 1 and mutation location annotated in Figure 2 and Supplementary Figure 1. 
The distribution of the main translocation subgroups, known to drive myeloma pathogenesis, 
did not differ significantly between patients with and without a mutation in any epigenetic 
modifier (Supplementary Figure 2).
Below we report a detailed analysis of the frequency and potential clinical impact of 
mutations in each class of epigenetic modifier.
Core and linker histone mutations: HIST1H1E is significantly mutated at myeloma 
diagnosis
The gene HIST1H1E, which encodes a linker histone H1 protein, was found to be 
significantly mutated in the MyXI cohort (14) at diagnosis with mutations in 2.8% of 
patients (13/463, p<1×10−10, q<1×10−10). Further analysis revealed recurrent non-
synonymous mutations in other histone 1 family genes including HIST1H1B (0.2%, 1/463), 
HIST1H1C (2.6%, 12/463), and HIST1H1D (0.6%, 3/463) with mutations in at least one of 
these genes (HIST1H1B-E) occurring in 6% (28/463) of patients. The mutations (Figure 2a) 
in these genes were predominantly missense SNVs affecting the globular domain of histone 
H1. HIST1H1B-E were aligned (Figure 2b) with sites affected by mutation highlighted. 
There were 3 sites of recurrent mutations at residues equivalent to alanine 61 and 65 and 
lysine 81 of HIST1H1E. There were also several additional mutations within the globular 
domain across variants located between residues 100–110. The globular domain of these 
genes is a region frequently mutated in other cancers including follicular lymphoma and 
diffuse large B cell lymphoma.(26, 27). The observations that the mutations occurred in a 
conserved region and there were no mutations in one known gene, HIST1H1A, supports the 
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hypothesis that these are not passenger mutations and may carry some significance to 
myeloma pathogenesis.
Mutations in HIST1H1B-E were tested for their impact on protein function using SIFT 
analysis. This analysis was possible in 29/31 mutations and 69% (20/29) were found to be 
damaging (Supplementary Table 5). HIST1H1B-E mutations did not have a prognostic 
impact (Supplementary Figure 3).
CCF analysis showed HIST1H1E and HIST1H1C mutations to be highly clonal (Figure 1) 
suggesting they are either acquired early in clonal development or selected for at progression 
to symptomatic disease, but nevertheless play an important role in myeloma pathogenesis in 
these patients.
Mutations were also seen in the core histone proteins 2A (4.5%, 21/463 patients, one 
frameshift mutation, remainder missense SNVs), 2B (3.7%, 17/463, one frameshift 
mutation, remainder missense SNVs), 3 (2.8%, 13/463, one frameshift, one nonsense, 
remainder missense SNVs) and 4 (1.7%, 8/463, all missense SNVs) but with a low 
frequency of mutation in each family member, with no individual gene being mutated in 
more than 4 patients. The total number of patients harbouring a mutation in any histone 
protein (linker or core) was 18% (83/463) with the presence or absence of any mutation 
having no effect on progression or survival.
Histone modifier mutations: Mutations/deletions in KDM6A/UTX may shorten overall 
survival from diagnosis
a) Methylation modifiers—Potentially deleterious mutations in histone 
methyltransferase/demethylase enzymes were found in 24% (112/463) of patients, though 
the percentage with each gene mutated was low (Figure 3). The most frequently mutated 
gene family in the methyltransferases was MLL/2/3/4/5 (7% of patients, 31/463. By gene: 
MLL 1.7%, 8/463, MLL2 1.3%, 6/463, MLL3 1.5%, 7/463 MLL4 1.5%, 7/463 and MLL5 
1.1%, 5/463) but no recurrent mutations were seen across variants. Of 36 mutations (across 
the 31 patients) 29 were missense SNVs, 4 nonsense SNVs, 2 splice site SNVs and 1 
frameshift mutation. As in other diseases mutations in MLL family genes are widely 
distributed across the genes with no conserved sites or regions of mutation (Supplementary 
Figure 1). The majority of mutations identified in our patients were novel but those 
previously identified in other diseases included one in MLL3, p.R190Q (endometrial) (20) 
and in MLL4, p.R297* (large intestine) (28). The presence of MLL family mutations in 
myeloma patients did not have an effect on progression-free or overall survival.
No mutations in the H3K27 methyltransferase EZH2 were detected, in contrast to the 
finding of recurrent mutations in other B cell malignancies. There were only 2 patients with 
mutations affecting the H3K36 methyltransferase MMSET, with none of the MMSET 
activating mutations at p.E1099K (previously identified in MM1.S myeloma cell line)(29) 
seen. EHMT2, the gene encoding the H3K9 methyltransferase G9a was mutated in 5/463 
patients (1%, all missense mutations) with one in the SET domain (p.Y1097F) and one in 
the ankyrin repeat ‘reader’ domain (p.E699K) (Supplementary Figure 1).
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The most frequently mutated demethylase gene was KDM3B, 1.5% (7/463) of patients with 
two splice site mutations, one nonsense mutation and 4 missense mutations, none of which 
have been previously identified in other cancers in the COSMIC database. The primary site 
of action of KDM3B is H3K9 and deletions of this gene have been implicated in 
myelodysplastic syndrome associated with 5q-. (30, 31)
KDM6A/UTX mutations were seen in 1.3% (6/463) of patients, were all missense mutations 
and were highly clonal (Figure 1). p.R118K, had been previously identified in lung cancer 
(32), p.Q398H in gastric adenocarcinoma (20) whilst another p.G66A occurred at the same 
residue as the p.G66D mutation previously identified in the OPM-2 myeloma cell line (10). 
Further analysis of this gene for whole exonic deletions increased the number of patients 
affected by a potentially inactivating lesion to 3% (15/463). Patients with a KDM6A 
mutation or deletion had a reduced overall survival (OS) compared to wild type on univariate 
analysis (Figure 4A) (medians not reached, logrank p=0.0498, percent alive at 2 years 51% 
95%CI (30, 85) vs 80% 95%CI (77, 84) with a similar trend for progression-free survival 
(PFS).
b) Acetylation modifiers—The most frequently mutated gene encoding a histone 
acetyltransferase (HAT) or deacetylase (HDAC) was the HAT EP300 mutated in 1.3% 
(6/463) of patients. Mutations in this gene have been previously identified in a number of 
other malignancies including DLBCL, where they are most commonly found in the HAT 
enzymatic domain.(33–35) One frameshift deletion (p.S90fs) and one nonsense mutation 
(p.Q1077*) are likely to result in an absence of functional protein. Of the 4 missense 
mutations one occurs in the active HAT domain (p.P1388S) and so may directly affect the 
catalytic function of the protein, whilst one in the bromodomain (p.V1079L) and two in the 
zinc finger binding domain (p.T1775P, p.G1778P) may still have significant effects on the 
protein function by affecting target binding. Mutations in CREBBP, a closely related 
member of the KAT3 family of histone acetyltransferases were also found in 3 patients. One 
mutation, p.R1360Q occurs at the same amino acid as the p.R1360* mutation seen in several 
diseases including B-NHL (33). EP300/CREBBP have a wide range of targets and are able 
to acetylate all four histones as well as being involved in many cellular processes linked to 
cancer such as cell cycle progression, p53 activity, DNA repair and apoptosis.(36)
There were no genes encoding histone reader proteins that were mutated in more than 1% 
(5/463) of patients at diagnosis.
DNA methylation modifier mutations: Mutations in DNA methylation modifiers are 
associated with a shorter overall survival from diagnosis
DNA methylation modifiers were mutated in 4% (17/463) of patients at diagnosis. This 
included specific mutations previously reported in numerous tumour types such as p.R132C 
in IDH1 previously reported in glioma, chondrosarcoma and AML (37–41), and p.R140W in 
IDH2 and p.C1378Y and p.Y1661* in TET2 previously reported in AML/MDS (42–44) and 
p.E784K in DNMT3A previously reported in biliary tract tumours (45). A mutation was also 
seen at p.E477K in DNMT3A, the site of recurrent mutation in AML and MPNs (p.E477* 
and p.E477fs)(46–48). Collectively, mutations in any DNA methylation modifier (TET1/2/3 
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n=11, IDH1/2 n=2 or DNMT1/3A/B n=6) were associated with a shorter OS on univariate 
analysis, Figure 4B (medians not reached, p=0.045, % alive at 2 years 58% 95%CI (39, 88) 
vs 80% 95%CI (76, 84). There was no significant effect of PFS. This effect on OS with no 
effect on PFS is explained by a significantly shortened post-progression survival for patients 
with mutations in DNA methylation modifiers compared to those without (p=0.002, logrank 
test, data not shown).
Chromatin remodelling complex mutations
The most frequently mutated genes involved in chromatin remodelling were CHD4 in 1.9% 
(9/463, all missense) of patients and CHD2 in 1.5% (7/463, one frameshift, six missense). 
Both are members of the nucleosome remodelling and deacetylase complex (NuRD). This 
highlights the potential role of the NuRD complex in myeloma pathogenesis however its 
action may not be entirely epigenetic as it has also been recently noted that CHD4 may also 
have roles in DNA damage repair and cell cycle progression independent of the NuRD 
complex and epigenetic activity.(49)
Other remodelling genes mutated in more than 1% of patients include ARID1A (encoding 
BAF 250a) in 1.3% (6/463, 2 nonsense and 4 missense) and ARID2 (encoding BAF200) in 
1.3% (6/463, 3 nonsense, 1 splice site, 2 missense). Their gene products are part of in the 
SWI/SNF (sucrose non-fermenting/ switch non-fermenting) remodelling complex and are 
responsible for its interaction with DNA. Mutations in genes encoding members of this 
complex have been previously demonstrated to be recurrently mutated in both solid tumours 
and haematologic malignancies in up to 20% of cancer patients overall.(50, 51) The 
mechanisms behind this have yet to be fully elucidated and in different diseases has been 
suggested to be related to the role of the SWI/SNF complex in DNA damage repair,(52) 
nucleosome positioning, DNAse hypersensitivity sites, the regulation of developmental gene 
expression and/or the interaction of the complex with both histone and DNA modifiers.(53) 
We found previously identified mutations at p.M918I in ARID1A (seen in renal cell 
carcinoma) (20) at p.Q937* in ARID2 (seen in biliary tract carcinoma and melanoma) (20, 
45), p.Q1611* in ARID2 (seen in squamous cell carcinoma) (54) and p.A1555S in ARID2 
(seen recurrently in head and neck carcinoma) (55).
Survival analysis
For each class of epigenetic modifier the progression-free and overall survival for those 
patients with a mutation in any gene within the class were compared to those patients 
without. In addition those patients with mutations of interest were compared to those 
without in the following cases, KDM6A mutations or deletions, MLL family gene mutations 
and Histone 1 family gene mutations. An effect on overall survival was found on univariate 
analysis for KDM6A mutations/deletions and DNA modifier mutations as described above. 
Multivariate analysis using a cox-regression model was therefore carried out considering 
other factors known to have an adverse effect on overall survival; presence of an adverse 
translocation t(4;14), t(14;16) or t(14;20), del17p, gain or amplification of 1q, international 
staging score and age >70. In this model DNA modifier mutations, in addition to del17p, ISS 
and gain or amplification of 1q remained significant but not KDM6A mutations/deletions. 
(Supplementary Table 6).
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The frequency of mutations in epigenetic modifiers increases following treatment
Longitudinal investigations are planned for the patients in the UK Myeloma XI trial, but at 
present the majority remain in remission. Therefore, in order to study the likely differences 
in the frequency of mutations in epigenetic modifiers as disease progresses we utilised 
available data for a series of 156 previously treated myeloma patients from the University of 
Arkansas for Medical Sciences (UAMS) who underwent targeted sequencing. Due to the 
different methods used we restricted our comparison to only those epigenetic modifier genes 
that have been sequenced in both studies (Supplementary Table 4) Results are summarised in 
Figure 5A and Supplementary Table 7 and show an increase in the number of patients with a 
mutation in any epigenetic modifier in samples taken at later stages of disease. There is a 
statistically significant increase in the number of patients with a mutation in any histone 
methyltransferase gene (6.9%, 32/463 MyXI vs 17%, 26/156 UAMS) or any DNA 
methylation modifier (1.9%, 9/463 MyXI vs 8.3%, 13/156 UAMS) and a notable increase in 
histone acetyl-transferase gene mutations (2.4%, 11/463 MyXI vs 7.1%, 11/156 UAMS). 
These changes appear to be the result of increases in mutations in MLL2, MLL3, SETD2, 
CREBBP, DNMT3A and TET2 (Figure 5B).
The variant allele frequency was compared between the MYXI and UAMS samples 
(Supplementary Figure 4) with no statistically significant differences seen. An analysis of 
the distribution of mutations across risk groups, as defined by gene expression profile risk 
score (GEP70) (Supplementary Figure 5) and UAMS molecular subgroups (Supplementary 
Figure 6) found a slight overrepresentation of the PR subgroup in those patients with an 
epigenetic modifier mutation compared to those without.
Of note in the UAMS dataset 2 of the 3 mutations in HIST1H1E had been previously 
identified, p.A65P in the MyXI dataset and p.P161S in a lymphoid neoplasm (COSMIC) 
whilst the third, p.A47V, occurred at the same residue as p.A47P seen in a MyXI patient. 
This supports the evidence of likely impact of HIST1H1E mutations in myeloma suggested 
by the MyXI analysis. Recurrent mutations were also seen in the UAMS dataset at the same 
location in IDH1, p.R132C and p.R132H, with p.R132C having been also identified in a 
MyXI patient.
Discussion
We report mutations within genes encoding epigenetic modifiers in myeloma with an impact 
on pathology and survival at diagnosis and an increased frequency after treatment. The 
spectrum of mutations in myeloma is broad with no single epigenetic modifier being 
mutated in a large proportion of patients. Several of the mutations identified have been 
previously related to cancer pathogenesis and/or may open possibilities for targeted 
treatment strategies for subgroups of patients. This work changes our understanding of the 
epigenetic landscape of myeloma exposing a wider spectrum of epigenetic processes than 
previously recognised, that may be altered in large numbers of patients, affecting disease 
biology and outcome.
One of our key findings is the significant mutation of HIST1H1E and similar mutations 
across Histone 1 family genes in diagnostic samples. Histone H1 acts to control the higher 
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order structure of chromatin by spacing nucleosomes and holding DNA in place as it winds 
around each nucleosome octamer. It has, therefore, been suggested to affect gene 
transcription via the modulation of the accessibility of DNA to transcription factors. 
Mutations in the histone H1 family genes have been found in other haematological 
malignancies including follicular lymphoma and diffuse large B cell lymphoma.(27, 56) In 
follicular lymphoma these were also noted to be predominantly in the globular domain and 
one such mutation (Ser102Phe) was functionally demonstrated to affect impaired ability of 
histone H1 to associate with chromatin.(56) This is close to several sites of mutation 
identified in our study between residues 100–110. More recently, histone H1 has also been 
shown to play a role in regulating DNA methylation via DNMT1 and DNMT3B binding and 
altering H3K4 methylation by affecting binding of the methyltransferases SET7/9.(26, 57) It 
might, therefore, be postulated that it is via these mechanisms that mutations in histone H1 
may have an oncogenic effect. Analysis of paired sample mutation and DNA methylation 
analysis will further inform this hypothesis.
HIST1H1E and HIST1H1C mutations (along with KDM6A and ARID2) were highly clonal, 
suggesting they may be acquired early in pathogenesis or selected for at progression to 
symptomatic disease. Our analysis estimates CCF using a method that correlates well with 
single cell analysis results; however in certain situations copy number alterations or 
polyclonality may yield anomalous CCF estimates for individual mutations. Future 
improvements in techniques for calculating CCF may further inform these results.
Our analysis identifies 3% of patients at diagnosis with a potentially inactivating lesion in 
KDM6A/UTX. This is lower than the frequency of mutations previously identified (10) and 
often reported of 6/58, 10%. This previous analysis, however, included cell lines, and when 
these are removed and only patient samples from the analysis considered the percentage 
with a lesion falls to 4% (2/49),in keeping with our study.
The Myeloma XI study pairs mutation and outcome data giving us the first opportunity to 
explore any possible association between epigenetic modifier mutations and outcome. 
Individual epigenetic modifier genes are mutated in small numbers of patients and so the 
size of our dataset limits the power to detect any specific gene effects. We therefore grouped 
mutations (11 groups as defined above) and on univariate analysis identified a detrimental 
effect on overall survival of KDM6A mutation/deletion (Log-rank p=0.0498) and DNA 
methylation modifiers (Log-rank p=0.045). If a Bonferroni correction for multiple testing 
were applied to this data the p-values obtained would fall above the level considered 
significant, however this arbitrary cut off may miss a clinically meaningful effect. Further 
investigation in future studies will help to clarify this. Notably the effect of DNA 
methylation modifier mutations on overall survival withstood multivariate analysis and in 
larger cohorts it would be of interest to investigate the independent association of mutations 
within this, and other groups, on outcomes.
Myeloma is part of a spectrum of malignancies arising from B cell populations at various 
stages of B cell ontogeny. Mutations in epigenetic modifiers are seen across this spectrum 
but we can now show that different patterns are seen dependent upon the biology of the 
population examined. Recurrent mutations in HIST1H1, MLL and EZH gene families have 
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been identified in diffuse large B cell lymphoma and follicular lymphoma.(26, 34) We show 
that HIST1H1 and MLL mutations are seen in myeloma, although at a much lower 
frequency, whereas EZH2 mutations are not seen, suggesting a different pathogenic 
mechanism. The different spectrum of epigenetic mutations is more marked when we 
compare lymphoid to myeloid diseases such as acute myeloid leukaemia, myelodysplastic 
syndromes and myeloproliferative neoplasms, where mutations in DNA modifying enzymes 
such as DNMT3A, IDH and TET2 predominate.(58, 59) We found mutations in these genes 
in myeloma, but at a much lower frequency.
Our results highlight possible targeted treatment approaches for patients either at diagnosis 
or at relapse. For example patients with a KDM6A/UTX mutation or deletion might be 
amenable to the use of EZH2 inhibitors, currently in the early stages of clinical development 
for lymphoma patients. Inhibiting EZH2, the H3K27 methyltransferase, may counteract the 
increased H3K27 methylation resulting from inactivation of the demethylase. A recent study 
also reports that ARID1A mutated cancers may be sensitive to EZH2 inhibition, 
demonstrating a synthetic lethal effect via the PI3-AKT pathway.(60) Patients with IDH 
mutations might be amenable to IDH inhibitors currently in early stages of development and 
a more global strategy might be possible for patients with mutations in DNA methylation 
modifiers with demethylating agents.
On comparison with results from focused sequencing of 156 previously treated patients we 
show an increase in the number of patients with a mutation in genes encoding a histone 
methyltransferases and DNA methylation modifiers. This suggests that these events may 
either play a role in disease progression or occur more frequently following exposure to 
induction chemotherapy in resistant subclones. The change in frequency of mutations in 
DNA methylation modifiers as myeloma progresses is supported by data showing a change 
in the methylation pattern at different disease stages.(3) There are several limitations to our 
comparison, however, including the different sequencing methods and depth. These results 
will, therefore, need to be validated in matched patient populations following relapse within 
a clinical trial setting using the same analysis method.
This whole-exome analysis of Myeloma XI patients at diagnosis is the first extensive 
analysis of the spectrum of mutations in epigenetic modifiers in a uniformly treated 
population in myeloma. An association with clinical outcome for KDM6A mutated or 
deleted patients, and mutations in DNA methylation modifiers is suggested in our dataset but 
will need validation in larger studies or meta-analysis due to the low overall frequency of the 
mutations. These data further emphasise the importance of epigenetics in myeloma and 
provide potential new targets for personalised therapeutic strategies for patients. Our 
findings support the use of sequencing-based diagnostics in myeloma both at diagnosis and 
relapse in order to identify potentially prognostic and/or targetable lesions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Translational relevance
Myeloma is a heterogeneous malignancy with disease in different subgroups of patients 
driven by abnormalities in multiple genes and/or molecular pathways. Treatment options 
and outcomes have improved over the last decade but novel approaches are still required. 
In this article we use whole-exome sequencing results from 463 presenting cases entered 
into the UK Myeloma XI study, and targeted sequencing of 156 previously treated cases, 
to report the wide spectrum of mutations in genes encoding epigenetic modifiers in 
myeloma. Using linked survival data from the large Myeloma XI study we identify 
lesions that may have prognostic significance in KDM6A and genes encoding DNA 
modifiers. We demonstrate an increase in the frequency of epigenetic modifier mutations 
of certain classes as disease progresses. Our analysis is particularly important as 
numerous mutations identified suggest potential targeted treatment strategies with agents 
either currently available or known to be in development, highlighting novel treatment 
approaches for patients.
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Figure 1. Cancer Clonal Fraction in genes encoding epigenetic modifiers
The proportion of tumor cells containing an SNV was calculated in the 370 samples with 
accurate copy number assessments and plotted as the CCF and 95% confidence interval for 
each sample with the indicated mutation, corrected for coverage. Mutations were considered 
clonal and shown in red if the upper bound of the CCF confidence interval was ≥ 95% and 
subclonal if the upper bound of the CCF confidence interval was <95%. The proportion of 
samples with each gene mutation that were clonal and sub-clonal are shown in the bar chart 
below the gene name. Epigenetic modifiers were analysed for CCF if they were mutated in 
≥5/463 (>1%) patients.
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Figure 2. Site of mutations in the genes encoding histone 1 variants
A, The common protein variants are shown with the globular domain of each highlighted in 
purple. The sites of mutation are indicated by the markers with red dots indicating missense 
mutations and purple dots frameshift mutations. There was 1 mutation in HIST1H1B in 1 
patient, 12 mutations in HIST1H1C in 12 patients, 3 mutations in HIST1H1D in 3 patients 
and 15 mutations in HIST1H1E in 13 patients. There were no mutations in HIST1H1A.
B, The common proteins of Histone 1 are aligned and labelled such that 1H1A/H1.1 
indicates the protein histone 1.1, encoded by gene HIST1H1A, 1H1B/H1.5 indicates the 
protein histone 1.5 encoded by gene HIST1H1B etc. The numbers indicate the amino acid 
number. The protein domains are indicated by the coloured bars overlying the protein 
sequence, green denotes the N terminal domain, purple the globular domain and red the C 
terminal domain. Mutations found in the patients sequenced are indicated by coloured 
square, pink = missense SNV, yellow = frame shift insertion and green = frame shift 
deletion. At some sites there was more than one patient with a mutation. The overlying 
arrows indicate amino acids where the mutations in different protein variants occur at the 
same equivalent amino acid residues.
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Figure 3. Mutations in histone methyltransferases and demethylases
The methyltransferases and demethylases located at their most commonly recognised site of 
activity on histone 3 are shown with the percentage of patients harbouring a mutation. Those 
in bold are mutated in 5 or more patients in the dataset.
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Figure 4. Overall survival is shorter in patients with a KDM6A mutation or deletion and those 
with a mutation in any DNA modifier
A, Kaplan-Meier curves showing patients with a KDM6A mutation or deletion (n=15, 
dashed) and those without (n=448, solid). Progression-free survival median mut/del 16.8 
months vs wild type 26.6 months (logrank p=0.695). Overall survival medians not reached, 
(logrank p = 0.0498). Percent alive at 2 years: mut/del 51% 95%CI (30, 85), wild type 80% 
95%CI (77, 84). Survival on x-axis is plotted as the time since randomisation.
B, Kaplan-Meier curves showing patients with a DNA modifier mutation (n=17: TET1/2/3 
n=11, IDH1/2 n=2 or DNMT1/3A/B n=6, dashed) and those without (n=446, solid). 
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Progression-free survival median mut/del not reached vs wild type 26.6 months (logrank 
p=0.852). Overall survival medians not reached, (logrank p = 0.0455). Percent alive at 2 
years: mut 58% 95%CI (39, 88), wild type 80% 95%CI (76, 84). Survival on x-axis is 
plotted as the time since randomisation.
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Figure 5. The frequency of mutations in genes encoding epigenetic modifiers at presentation and 
following treatment by class of epigenetic modifier
A, A comparison between the percentage of patients with a mutation in each class of 
epigenetic modifier at presentation (Myeloma XI data, shown in black bars) and after 
treatment (UAMS data, shown in gray bars). There is a significant increase in the percentage 
of previously treated patients with a mutation for those groups indicated by *. (z-test of 
difference in proportions P<0.05). Those comparisons remaining significant after multiple 
test correction (Boferroni method) are indicated by **. Full data is shown in supplementary 
table 7. Only mutations in genes sequenced in both studies (i.e. the genes sequenced in the 
UAMS F1 dataset, supplementary table 4) were included for this comparison.
B, The frequency (%) of mutations in genes of interest within each class
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Table 1
Epigenetic genes mutated in ≥5/463 (>1%) newly diagnosed patients in Myeloma XI dataset
Gene
No of patients
(total = 463) Percentage
ARID1A 6 1.30%
ARID2 6 1.30%
ARID4A 5 1.08%
ARID5B 5 1.08%
CHD2 7 1.51%
CHD4 9 1.94%
EHMT2 5 1.08%
EP300 6 1.30%
HIST1H1C 12 2.59%
HIST1H1E 13 2.81%
KDM3B 7 1.51%
KDM6A 6 1.30%
MLL 8 1.73%
MLL2 6 1.30%
MLL3 7 1.51%
MLL4 7 1.51%
MLL5 5 1.08%
SETD2 6 1.30%
SETDB1 5 1.08%
TET2 5 1.08%
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